Request Demo

Last update 23 Dec 2025

Lurbinectedin

Last update 23 Dec 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Lurbinectedin (USAN/INN), Lurbinectedina, Tryptamicidin

+ [9]

Target

DNA

Action

inhibitors

Mechanism

DNA inhibitors(DNA inhibitors)

Therapeutic Areas

NeoplasmsRespiratory DiseasesOther Diseases+ [6]

Active Indication

Extensive stage Small Cell Lung CancerSmall Cell Lung CancerLeiomyosarcoma+ [21]

Inactive Indication

acute leukemiaAdvanced cancerAdvanced Malignant Solid Neoplasm+ [18]

Originator Organization

Active Organization

+ [9]

Inactive Organization-

License Organization

Megapharm Ltd.

Luye Pharma Group Ltd.

Chugai Pharmaceutical Co., Ltd.

+ [11]

Drug Highest PhaseApproved

First Approval Date

United States (15 Jun 2020),

Small Cell Lung Cancer

RegulationAccelerated Approval (United States), Orphan Drug (United States), Orphan Drug (European Union), Orphan Drug (South Korea), Orphan Drug (Australia), Overseas New Drugs Urgently Needed in Clinical Settings (China), Conditional marketing approval (Israel), Emergency Use Authorization (China), Priority Review (United States), Conditional marketing approval (China), Priority Review (China), Orphan Drug (Switzerland)

Structure/Sequence

Molecular FormulaC41H44N4O10S

InChIKeyYDDMIZRDDREKEP-HWTBNCOESA-N

CAS Registry497871-47-3

Clinical Trials associated with Lurbinectedin

NCT07153055

/ Not yet recruitingPhase 1/2IIT

Phase I/II Trial of Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer

This open-label, Phase I/II trial is studying the safety and effectiveness of an experimental drug combination, lurbinectedin with osimertinib, against a rare type of cancer known as transformed small cell lung cancer (SCLC).

Start Date01 May 2026

Sponsor / Collaborator

Indiana University

[+1]

NCT07141771

/ Not yet recruitingPhase 1/2IIT

An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing

Small-cell lung cancer (SCLC) has a high degree of malignancy and extremely poor prognosis, slow progress in the treatment of ES-SCLC, and a more ideal posterior therapy needs to be explored. This is an I / II, phase umbrella study to explore afterline treatment options following progression of frontline platinum-containing therapy for small cell lung cancer.
This study includes 2 parts:
Part 1 will enroll patients with end of first-line platinum-containing therapy and progression interval of less than 180 days or more of second-line therapy (no first-line relapse time required).
Part 2 will enroll patients with end of first-line platinum-containing therapy greater than 180 days.
Based on the optimal selection of patients with recurrent broad-stage small cell lung cancer with different molecular and clinical characteristics, we further explored different treatment modes suitable for different populations through umbrella cohort studies.

Start Date31 Dec 2025

Sponsor / Collaborator

Cancer Hospital Chinese Academy of Medical Sciences

NCT07155174

/ RecruitingPhase 2

A Phase 2 Randomized, Open Label, Multicenter Study to Evaluate the Optimal Dose, Safety, and Efficacy of ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Subjects With Previously Untreated Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Small cell lung cancer (SCLC) is characterized by aggressive and rapid growth and a tendency to develop early spread to distant sites including mediastinal lymph nodes, liver, bones, adrenal glands, and brain. The purpose of this study is to assess safety, dose, change in disease activity of ABBV-706 given with atezolizumab, compared to standard of care (SOC) treatment (etoposide, carboplatin, atezolizumab, and optional lurbinectedin).
ABBV-706 is an investigational drug being developed for the treatment of SCLC. There are multiple treatment arms in this study. Participants will either receive ABBV-706 given with atezolizumab, at 1 of 2 doses, or SOC. Approximately 180 adult participants will be enrolled in the study across sites worldwide.
In the safety lead-in, participants with SCLC will receive intravenous (IV) ABBV-706 in 1 of 2 doses with IV atezolizumab, or IV SOC. In the expansion portion of the study, participants with SCLC will receive IV ABBV-706 in 1 of 2 doses with atezolizumab, or IV SOC, until the optimal dose of ABBV-706 is determined. The estimated duration of the study is up to 69.5 months.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, questionnaires, and scans.

Start Date25 Nov 2025

Sponsor / Collaborator

AbbVie, Inc.

100 Clinical Results associated with Lurbinectedin

100 Translational Medicine associated with Lurbinectedin

100 Patents (Medical) associated with Lurbinectedin

207

Literatures (Medical) associated with Lurbinectedin

01 Dec 2025·CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Maintenance after first-line treatment for advanced soft tissue sarcoma

Review

Author: Pautier, Patricia ; Penel, Nicolas ; Blay, Jean-Yves

Doxorubicin-based chemotherapy remains the best treatment modality for patients with advanced soft tissue sarcoma (STS), despite limited therapeutic efficacy. Moreover, subsequent salvage treatments exhibit reduced effectiveness. Consequently, the investigation of maintenance therapy in patients with non-progressive STS is pertinent. We reviewed non-randomized trials, although their interpretation was constrained by the lack of internal comparators. We examined eight randomized trials investigating maintenance therapy in patients with STS. Among seven trials assessing continuation maintenance therapy, two demonstrated significant improvement in progression-free survival (PFS): trabectedin following doxorubicin/trabectedin treatment in patients with advanced/metastatic leiomyosarcoma and anlotinib following epirubicin/anlotinib treatment across all histological subtypes. One trial investigating switch maintenance with regorafenib reported significant improvement in PFS in patients with nonadipocytic STS. Doxorubicin/trabectedin in patients with leiomyosarcoma yielded significant improvement in overall survival. Promising results observed with olaratumab in a randomized phase II trial were not confirmed in a subsequent phase III trial. Early phase trials involving doxorubicin/trabectedin in patients with liposarcoma, doxorubicin/lurbinectedin in patients with leiomyosarcoma and those with liposarcoma, and doxorubicin/pembrolizumab revealed promising associations that warrant exploration in future randomized trials. For pembrolizumab, biomarkers for appropriate patient selection are lacking. This literature review can aid in the design of future maintenance trials.

01 Nov 2025·LUNG CANCER

Second-line treatment strategies and clinical outcomes after progression on chemoimmunotherapy in extensive-stage small-cell lung cancer

Article

Author: Fantoni, A ; Rogers, J ; Clay, T ; Solomon, B ; Warburton, L ; Da Silva, I ; Andreas, V ; Faltys, M ; Hughes, B G M ; Alexander, M ; Sullivan, I ; Brown, L J ; Parakh, S ; Arulananda, S ; Kao, S ; Bowyer, S ; Itchins, M ; John, T

BACKGROUND:

In extensive-stage small cell lung cancer (ES-SCLC), chemoimmunotherapy (CIO) is the standard first-line (1L). However, real-world data describing second-line (2L) outcomes post-CIO remain limited. We assessed 2L outcomes following progression after 1L CIO.

METHODS:

We analyzed retrospective multicenter patient data from the AUstralasian thoRacic cancers lOngitudinal cohoRt study and biobAnk (AURORA). Population characteristics and treatment outcomes were summarized using descriptive statistics. Survival was estimated using the Kaplan-Meier method; covariate effects were evaluated using Cox proportional hazards models.

RESULTS:

We included 111 patients from 10 Australian centers. Median age was 65 years (Q1-Q3: 58-72); 58 % male, 96 % current or former smokers, and 74 % had ECOG ≤ 1. Patients received a median of 8 CIO cycles (97 % atezolizumab) before 2L treatment. Common 2L regimens included lurbinectedin (32 %), carboplatin/etoposide rechallenge (21 %), CAV (20 %), and topotecan (9 %). Platinum-sensitive relapse (≥6-month chemotherapy-free interval) occurred in 27 %. Among rechallenge patients, the median interval from 1L to 2L platinum was 192 days (Q1-Q3: 155-308). The 2L objective response rate was 22 %. Median duration of response was 2.2 months (95 % CI: 1.8-3.3), progression-free survival 2.9 months (95 % CI: 2.5-3.5), and overall survival 5.8 months (95 % CI: 4.6-6.4). Rechallenge with carboplatin/etoposide was associated with numerically longer survival compared to other 2L agents. No significant differences in PFS or OS were observed among non-rechallenge regimens.

CONCLUSION:

2L survival outcomes post-CIO were similar to historical results after chemotherapy alone. Despite 1L immunotherapy, 2L response rates and survival remain poor, underscoring the need for more effective strategies in ES-SCLC.

21 Oct 2025·Future Oncology

IDeate-Lung02: a Phase 3 study of second-line ifinatamab deruxtecan in patients with relapsed small cell lung cancer

Article

Author: Byers, Lauren ; Hayashi, Hidetoshi ; Owonikoko, Taofeek K. ; Rudin, Charles M. ; Cheng, Ying ; Garcia, Cecilio Roi ; Qian, Meng ; Pérol, Maurice ; Paz-Ares, Luis ; Tang, Mei ; Hu, Haichuan ; Godard, Juliette

Patients with small cell lung cancer (SCLC) have poor prognosis and limited treatment options beyond first-line therapy. B7 homolog 3 (B7-H3) is minimally expressed in normal tissues but highly expressed in SCLC. Ifinatamab deruxtecan (I-DXd), a B7-H3-directed antibody-drug conjugate, has demonstrated promising efficacy and a manageable safety profile in various tumours, including SCLC. IDeate-Lung02 is a global, randomized, open-label Phase 3 study of ~540 patients with relapsed SCLC. Adults with one prior line of platinum-based systemic therapy, ECOG performance status 0-1, and ≥1 measurable lesion (per RECIST 1.1) are eligible for study participation. Patients with asymptomatic untreated or previously treated brain metastases may participate. Patients are randomized 1:1 to receive I-DXd 12 mg/kg intravenously every 3 weeks or treatment of physician's choice (topotecan, amrubicin, or lurbinectedin). Dual primary endpoints are objective response rate (ORR) by blinded independent central review (BICR) and overall survival. Secondary endpoints include ORR by investigator; progression-free survival, duration of response, disease control rate, and time to response, all by BICR and investigator; patient-reported outcomes; and safety. IDeate-Lung02 will ascertain whether I-DXd treatment after only one prior line of systemic treatment improves outcomes for patients with relapsed SCLC compared with topotecan, amrubicin, or lurbinectedin.Clinical Trial Registration: NCT06203210.

169

News (Medical) associated with Lurbinectedin

19 Dec 2025

·www.biospace.com

Patient Deaths Put Merck, Daiichi Sankyo’s Antibody-Drug Conjugate on Hold

iStock, Suchat longthara The fatalities were attributed to interstitial lung disease, a known side effect of Daiichi Sankyo’s DXd-based antibody-drug conjugates. A spokesperson declined to say how many patients died. The FDA has placed a partial clinical hold on Merck and Daiichi Sankyo’s late-stage development program for their antibody-drug conjugate ifinatamab deruxtecan after “a higher than expected” number of deaths were detected, according to several media reports on Thursday. The companies were studying ifinatamab deruxtecan—more commonly known as I-DXd—in the Phase III IDeate-Lung02 trial , which has enrolled more than 500 patients with relapsed small cell lung cancer. Participants were treated with I-DXd or with an active chemotherapy comparator, including topotecan, amrubicin and lurbinectedin. In a joint statement to Fierce Biotech , a spokesperson for the companies said that they detected “a higher than anticipated incidence of grade 5 interstitial lung disease (ILD) events” in IDeate-Lung02, which prompted Daiichi Sankyo to voluntarily halt recruitment. The FDA has since also applied a partial freeze on the study. The spokesperson did not indicate how many patients died. “ILD is a potentially fatal side effect known to be associated with all of Daiichi’s DX ADCs [antibody-drug conjugates],” Jefferies analysts explained in a Thursday note to investors. “This has not stopped Enhertu and Datroway from being approved.” The spokesperson said that the hold “does not impact other studies in the I-DXd clinical development program.” The partners are working with the regulator and with an independent data board to best understand the mortalities and determine the next steps for the affected study. Merck and Daiichi Sankyo teamed up in October 2023 to collaborate on three DXd-based ADCs—anti-cancer constructs that consist of an antibody and an exatecan derivative, which is a topoisomerase I inhibitor that causes cancer cells to die. In June 2024, the partners ran into a regulatory roadblock when the FDA declined to approve patritumab deruxtecan for locally advanced or metastatic non-small cell lung cancer. The rejection hinged on third-party manufacturing problems; the FDA did not identify issues with the drug’s efficacy or safety. The companies rallied in September of this year when I-DXd showed a 48.2% confirmed objective response rate in IDeate-Lung02—the same study that is now under partial hold. Aside from Merck, AstraZeneca has also bought into the promise of Daiichi Sankyo’s DXd platform. The partners have secured two approvals: one in late 2019 for Enhertu and another in January this year for Datroway .

ADCDrug ApprovalPhase 3Clinical ResultAccelerated Approval

19 Dec 2025

·www.biopharmadive.com

Patient deaths put Merck, Daiichi’s ADC trial on partial hold

The Food and Drug Administration has put a partial clinical hold on one of Merck & Co. and Daiichi Sankyos antibody-drug conjugates following an unexpected number of deaths in a late-stage clinical trial.Daiichi initiated a voluntary pause recruiting and enrolling the trial, called IDeate-Lung02, after higher than anticipated incidence of grade 5 interstitial lung disease events, a spokesperson for Merck and Daiichi said in a statement to BioPharma Dive. Following the pause, the FDA verbally placed the trial on a partial clinical hold in October. The spokesperson did not say the number of deaths recorded.During the hold, Daiichi, along with the FDA and an independent committee will review the safety data and decide on any necessary further actions. Trial enrollees will be able to continue treatment, but no new participants will be recruited.The experimental drug, called ifinatamab deruxtecan, or I-DXd, is one of three ADCs Merck gained the rights to through a major licensing deal with Daiichi in 2023. ADCs, which link an antibody to a toxic payload, are meant to more effectively target and destroy cancer cells while sparing the surrounding healthy tissue.Though theyve been around for decades, ADCs became a major asset for drug developers relatively recently. AstraZeneca and Daiichi, for instance, found success with their medicines Enhertu and Datroway, which are approved to treat several cancers. However, interstitial lung disease is a known side effect of Daiichis antibody-drug conjugates, and is listed on the labeling of Datroway and Enhertu.The Phase 3 trial testing I-DXd enrolled over 500 participants with small cell lung cancer, who were treated with the drug or randomized to receive a chemotherapy regimen of either topotecan, lurbinectedin or amrubicin.Expectations for the drug rose after Phase 2 results demonstrated promising objective response rates in people with pretreated, extensive-stage small cell lung cancer. The FDA granted breakthrough therapy designation to I-DXd based on those results.The spokesperson said the companies are in discussions with global regulatory authorities over the latest trial data, but would not comment further on regulatory strategy.The clinical hold represents another blow to Mercks ADC program. Earlier this year, the company pulled its approval application for a therapy called patritumab deruxtecan, after finding it did not extend survival in people who have a certain kind of non-small cell lung cancer with mutations in the EGFR gene. The FDA also rejected patritumab deruxtecan last year due to third-party manufacturing problems.The spokesperson said the clinical hold does not impact other studies of I-DXd.Merck and Daiichi are evaluating the potential impact of the hold on trial readout data timing, which is currently expected in 2027. '

Phase 3Breakthrough TherapyADCLicense out/inPhase 2

28 Nov 2025

·www.immedica.com

Zepzelca® (lurbinectedin) in combination with atezolizumab approved as first-line maintenance therapy for extensive-stage small cell lung cancer in United Arab Emirates (UAE)

These cookies allow the website to remember choices you make and provide enhanced, more personal features. The information these cookies collect may be anonymized and they cannot track your browsing activity on other websites. These cookies allow us to recognise and count the number of visitors and to see how visitors move around our website when they are using it. This helps us to improve the way our website works, for example, by ensuring that users are finding what they are looking for easily. These cookies enable the website to provide enhanced functionality and personalisation. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies then some or all of these services may not function properly. Stockholm, Sweden, November 28, 2025 – Immedica today announced that the Emirates Drug Establishment has granted approval for Zepzelca® (lurbinectedin) in combination with atezolizumab (Tecentriq®) as a maintenance treatment for adults with extensive-stage small cell lung cancer (ES-SCLC) whose disease has not progressed after first-line induction therapy with atezolizumab, carboplatin and etoposide. "This approval is an important milestone for people living with extensive-stage small cell lung cancer in the UAE. Access to new treatment options is essential in a disease where time is critical, and we are committed to improving the day-to-day life for patients and their families." – said Anders Edvell, CEO, Immedica. The approval is based on results from the Phase 3 IMforte trial, which showed that the lurbinectedin and atezolizumab combination reduced the risk of disease progression or death by 46% and the risk of death by 27%, compared to atezolizumab maintenance therapy alone. Following four cycles of induction therapy, from the point of randomization the median overall survival (OS) for the combination regimen was 13.2 months versus 10.6 months (stratified hazard ratio [HR]=0.73; 95% CI: 0.57–0.95; p=0.0174). From the point of randomization, median progression-free survival (PFS) by independent assessment was 5.4 months versus 2.1 months, respectively (stratified HR=0.54, 95% CI: 0.43–0.67; p<0.0001). Safety was consistent with the known safety profiles of both treatments. The results were presented at the 2025 American Society of Clinical Oncology (ASCO) annual meeting and simultaneously published in The Lancet. Immedica has a strategic partnership with PharmaMar, where Immedica holds the distribution rights to Zepzelca in the Nordics, the UK & Ireland, Central Eastern Europe as well as in the Middle East and North Africa. About Zepzelca® (lurbinectedin) Zepzelca is a synthetic analog of the natural marine-based tetrahydroisoquinoline trabectedin. It acts as an alkylating agent that inhibits oncogenic transcription leading to tumor cell death and it modulates the tumor microenvironment. On November 25, 2025, the Emirates Drug Establishment approved Zepzelca in combination with atezolizumab or atezolizumab and hyaluronidase-tqjs, as maintenance treatment for adults with ES-SCLC whose disease has not progressed after first-line induction therapy with atezolizumab or atezolizumab and hyaluronidase-tqjs, carboplatin and etoposide. On July 01, 2021, the United Arab Emirates Ministry of Health & Prevention issued a Product Marketing Authorization approval for Zepzelca monotherapy for the treatment of adult patients with metastatic SCLC with disease progression on or after platinum-based chemotherapy. About small cell lung cancer (SCLC) SCLC is an aggressive form of lung cancer characterized by rapid growth, early metastasis, and limited therapeutic options. It accounts for about 10–15 % of all lung cancer cases and tends to present at an advanced stage, often requiring systemic therapy. Because of its aggressive nature and propensity for relapse, the prognosis remains poor. About PharmaMar PharmaMar is a biopharmaceutical company headquartered in Madrid, Spain, specializing in the discovery, development, and commercialization of anticancer therapies derived from marine biodiversity. The company focuses its R&D efforts on rare and difficult-to-treat cancers, leveraging a proprietary platform of marine-derived compounds and strong collaborations with academic and industry partners. For more information, visit www.pharmamar.com About Immedica Immedica is a pharmaceutical company, headquartered in Stockholm, Sweden, focused on the commercialization of medicines for rare diseases and specialty care products. Immedica’s capabilities cover marketing and sales, compliance, pharmacovigilance, quality assurance, regulatory, medical affairs and market access, as well as a global distribution network serving patients in more than 50 countries. Immedica is fully dedicated to helping those living with diseases which have a large unmet medical need. Immedica’s therapeutic areas are within RARE metabolic, RARE hematology & oncology, RARE neurology and specialty care. Immedica was founded in 2018 and employs today around 150 people across Europe, the Middle East and the United States. Immedica is backed by the investment firms KKR and Impilo. For more information visit www.immedica.com. Immedica contact: Linda Holmström VP, Head of Communication linda.holmstrom@immedica.com Press release - Zepzelca approval UAE first-line treatment Immedica Pharma AB Solnavägen 3H SE-113 63 Stockholm Follow us to stay up to date with what is happening at Immedica. We believe we have an important role to fill in society – bringing new, innovative treatments to patients with rare diseases. Focus areas are within RARE metabolic, RARE neurology, RARE hematology & oncology and specialty care. We operate products from phase 2 and all the way to mature products. ESG is an integrated part of our business model. Stay up to date with our latest news. Telephone: +46 (0) 8 533 39 500 E-mail: info@immedica.com

Clinical ResultDrug ApprovalPhase 3

100 Deals associated with Lurbinectedin

External Link

KEGG	Wiki	ATC	Drug Bank
D11644	Lurbinectedin	L01XX	DB12674

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Extensive stage Small Cell Lung Cancer	United States	Jazz Pharmaceuticals Ireland Ltd.	02 Oct 2025
Small Cell Lung Cancer	United States	Jazz Pharmaceuticals Ireland Ltd.	15 Jun 2020

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Leiomyosarcoma	Phase 3	United States	Pharma Mar SA	21 Sep 2023
Leiomyosarcoma	Phase 3	Austria	Pharma Mar SA	21 Sep 2023
Leiomyosarcoma	Phase 3	Belgium	Pharma Mar SA	21 Sep 2023
Leiomyosarcoma	Phase 3	France	Pharma Mar SA	21 Sep 2023
Leiomyosarcoma	Phase 3	Germany	Pharma Mar SA	21 Sep 2023
Leiomyosarcoma	Phase 3	Italy	Pharma Mar SA	21 Sep 2023
Leiomyosarcoma	Phase 3	Netherlands	Pharma Mar SA	21 Sep 2023
Leiomyosarcoma	Phase 3	Poland	Pharma Mar SA	21 Sep 2023
Leiomyosarcoma	Phase 3	Portugal	Pharma Mar SA	21 Sep 2023
Leiomyosarcoma	Phase 3	Spain	Pharma Mar SA	21 Sep 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05091567 (IMforte, ESMO2025) Manual	Phase 3	Extensive stage Small Cell Lung Cancer First line \| Maintenance	483	Lurbinectedin + Atezolizumab	xnztenegea(fsyxotfnxh) = twhvxjulxo peymflkgqg (pojdzdomaw ) View more	Positive	17 Oct 2025
				Atezolizumab	xnztenegea(fsyxotfnxh) = qalxombaus peymflkgqg (pojdzdomaw ) View more
NCT05876715 (ESMO2025)	Phase 1/2	Locally Advanced Soft Tissue Sarcoma First line	40	Lurbinectedin + Ipilimumab + Nivolumab (Phase 1)	lhuopvmvmw(rdjbrgwttc) = ekotrdnlnc gpjnisodsm (hsaxgqrgnm ) View more	Positive	17 Oct 2025
				Lurbinectedin + Ipilimumab + Nivolumab (Phase 2)	oitljujykz(wzvjtwiniw) = aqevgncspu ptutpmvlih (vvzetibgwf ) View more
NCT05072106 (CTgov)	Phase 1	Advanced Malignant Solid Neoplasm	11	Lurbinectedin+Bosentan (Bosentan Co-administration Cycle)	dkxgeipyzo(qmecmsznru) = ypxzctqseg qchaalsbzk (gekrxpmzlu, 54.81) View more	-	16 Sep 2025
				Lurbinectedin (Single Agent Lurbinectedin Cycle)	dkxgeipyzo(qmecmsznru) = zaucsujlmu qchaalsbzk (gekrxpmzlu, 49.56) View more
NCT05063318 (CTgov)	Phase 1	Advanced Malignant Solid Neoplasm	14	lurbinectedin+ITZ (ITZ+LRB)	grjorxavta(mcxtokqcqm) = fxbudexthd ofdnpkewsu (qhfwvuefxf, 73.9) View more	-	02 Sep 2025
				LRB (LRB Alone)	grjorxavta(mcxtokqcqm) = kyvirbyigs ofdnpkewsu (qhfwvuefxf, 77.37) View more
NCT05091567 (IMforte, Pubmed \| Lancet) Manual	Phase 3	Extensive stage Small Cell Lung Cancer First line \| Maintenance	483	Lurbinectedin + Atezolizumab	wxdgjozmsl(ykfiydmogj): HR = 0.54 (95% CI, 0.43 - 0.67), P-Value = <0.0001 View more	Positive	01 Jun 2025
				Atezolizumab
NCT05091567 (IMforte, ASCO2025) Manual	Phase 3	Extensive stage Small Cell Lung Cancer Maintenance \| First line	660	Lurbinectedin + Atezolizumab	jllajrsatt(qdupjdgvrn) = mtgkefaize nqtvikzeqs (atdzvznliu, 4.2 - 5.8) View more	Positive	30 May 2025
				Atezolizumab	jllajrsatt(qdupjdgvrn) = abqgikedwp nqtvikzeqs (atdzvznliu, 1.6 - 2.7) View more
NCT04253145 (2SMALL, ASCO2025) Manual	Phase 1/2	Advanced Lung Small Cell Carcinoma Second line	151	lurbinectedin + atezolizumab (Cohort 1, progression after one prior platinum-based chemotherapy alone)	qoanhjjqid(bliqlurzli) = jgxmlwslec dwnpvdgfmu (ppyrdpexyg, 32.27 - 56.63) View more	Positive	30 May 2025
				lurbinectedin + atezolizumab (Cohort 2, combined with PD-1/ PD-L1 blockade)	qoanhjjqid(bliqlurzli) = zfvkusrvyv dwnpvdgfmu (ppyrdpexyg, 27.18 - 48.7) View more
ASCO2025	Not Applicable	Small Cell Lung Cancer Second line \| Third line	61	Lurbinectedin as second-line therapy	emazrnrjyu(srulerpxdb) = 37.5% jfhyteywmd (nllyohorlx ) View more	Positive	30 May 2025
				Lurbinectedin as third-line therapy
NCT04607954 \| NCT04358237 \| NCT04253145 \| NCT06497530 (ASCO2025)	Phase 1/2	Extensive stage Small Cell Lung Cancer	54	Lurbinectedin + Pembrolizumab	nupslyxkzh(psocgkfimd) = twfqepkwgs ttldjenbyl (zwuwfdhfvt ) View more	Positive	30 May 2025
				Lurbinectedin + Atezolizumab	fautegnjii(xfdrplfhqj) = wcgeyhcflt wyjvqopput (qaqkprnktt ) View more
ASCO2025	Not Applicable	Extensive stage Small Cell Lung Cancer Second line	256	Lurbinectedin	mlpvmnmbpr(cgvdwqaydj) = fcptptyzxj hhnqzapzpl (iolqyvupza, 0.681 - 0.685) View more	Positive	30 May 2025

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis